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Abstract
Background: The global obesity epidemic has created new challenges, including 
 venous thromboembolisms (VTE) in obese adolescents. The data on whether to  reduce 
the dose of low- molecular heparin in obese adults is conflicting, and information on 
adolescent patients is scarce.
Objectives: Our primary goal was to describe dosing, anti- Xa levels, and outcomes of 
overweight and obese adolescents who received reduced doses of enoxaparin at the 
initiation of therapy. The secondary goal was to compare their outcomes to over-
weight and obese adolescents who received standard 1 mg/kg dosing to determine if 
future trials for dose reduction are warranted.
Patients/Methods: We performed a retrospective cohort study of overweight and 
obese patients between the ages of 12 and 18 years old diagnosed with VTE who 
were treated with reduced dosing (RD) of enoxaparin, comparing their dosing, anti- Xa 
levels, and outcomes to overweight and obese adolescents who received standard 
dosing (SD).
Results: RD patients (n=19) achieved therapeutic mean initial anti- Xa levels that were 
similar to SD patients (n=11). Of the RD patients, 53% did not require dose adjust-
ments during treatment. Two RD patients had thrombus progression. A total of 25 
patients ultimately completed therapy with RD.
Conclusions: Future trials are warranted to evaluate the efficacy and safety of reduced 
dosing of enoxaparin to treat overweight and obese adolescents with VTE.
K E Y W O R D S
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Essentials
• Data is scarce on enoxaparin dosing for obese adolescents with venous thromboembolism (VTE).
• Overweight and obese adolescents treated with reduced enoxaparin dose (RD) were reviewed.
• Initial enoxaparin doses calculated using actual body weight may be greater than what is needed.
• Trials are warranted to evaluate RD enoxaparin for overweight and obese adolescents with VTE.
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1  | INTRODUCTION
The World Health Organization has reported an obesity epidemic 
affecting many countries, even developing, poor nations.1 According 
to the Centers for Disease Control, the prevalence of obesity in the 
United States in the 12- 19 year age range has already nearly doubled 
from 10.5% (1988- 1994) to 20.6% (2013- 2014), while extreme obe-
sity (defined as ≥ 120th percentile) has tripled from 2.6% (1988- 1994) 
to 9.1% (2013- 2014).2 Similar to obese adults, obese adolescents have 
a higher risk of venous thromboembolism (VTE) compared to non- 
obese adolescents.3–7 As the global obesity epidemic continues, there 
will be a greater need to treat overweight and obese adolescents for 
VTE. This population poses a dosing dilemma when prescribing low- 
molecular- weight heparins (LMWH)—commonly enoxaparin.
There is little data to guide providers on how to dose enoxaparin 
in overweight and obese adolescents. First, the recommendations by 
the American College of Chest Physicians (ACCP) for weight- adjusted 
dosing of enoxaparin to treat pediatric VTE are based largely on adult 
studies, despite reduced predictability of the anticoagulant effect in 
children compared to adults when using weight- adjusted dosing.8,9 
Thus, enoxaparin is used off label in children. Second, obesity can af-
fect the pharmacokinetics of enoxaparin, although it is unclear if the 
net effects warrant dose modifications.10–14 Third, the therapeutic 
ranges recommended by the College of American Pathologists have 
not been validated in clinical trials.15 Finally, the monitoring of enoxa-
parin utilizing anti- Xa levels in adults is controversial, and no data exist 
for adolescents.16,17
Adolescent VTE, most commonly deep vein thrombosis (DVT) and 
pulmonary embolism (PE), patterns and mortality rates are different 
compared to adult VTE.18 For example, PE in adolescents is rarely fatal 
and likely secondary to fewer comorbidities in the adolescent pop-
ulation.19 In addition, adult dose- reduction strategies such as dose- 
capping may not apply for an obese adolescent who weighs less.12,13,20 
Because of these differences, data from obese adolescents is neces-
sary and should not be extrapolated from trials designed for obese 
adults.
To our knowledge, there has been no study describing dose mod-
ifications in obese adolescents diagnosed with VTE. Two case series 
described enoxaparin prophylaxis in obese adolescents, not treat-
ment.21,22 The small numbers in those studies limit the interpretation 
of their enoxaparin pharmacokinetic data.
At our institution, the Pediatric Hematology/Oncology (PHO) team 
is consulted for all adolescent patients diagnosed with VTE. The initial 
dosing of enoxaparin is determined and ordered at a pediatric hema-
tologist’s discretion with some patients receiving doses less than the 
ACCP’s recommendations. After approval by the institution’s institu-
tional review board, we performed a retrospective cohort study with 
the primary goal of describing dosing, anti- Xa levels, and outcomes 
of overweight and obese adolescents who received upfront reduced 
dosing (RD) of enoxaparin. We also compared these patients to over-
weight and obese adolescents treated at our institution who received 
standard dosing (SD) to determine if future trials to evaluate the effi-
cacy and safety of dose reduction are warranted.
2  | MATERIALS AND METHODS
2.1 | Study population and data
Our PHO team, as directed by a pediatric hematologist, manages 
all aspects of care for adolescents diagnosed with VTE including 
dosing, anti- Xa level monitoring, and follow- up. Our PHO team 
maintains an internal database of any new patients we encounter, 
captured by new consultation notes and billing records, collecting 
the patients’ names, medical record numbers, dates of birth, and 
diagnoses.
This database was queried using the terms “thrombosis,” “throm-
bus,” “DVT,” “vein,” “clot,” “PE,” “pulmonary,” “emboli,” and “stroke.” 
The electronic and written medical records from hospitalization and/
or outpatient follow- ups were reviewed. Patients were included if 
they were ≥12 and ≤18 years old; overweight or obese, defined as 
a body mass index (BMI) ≥ 85th percentile for age and sex23; and 
received enoxaparin for treatment of VTE between January 2004 and 
December 2014. Patients with renal disease—defined as having any 
pre- existing renal diagnosis, undergoing dialysis, or carrying a diag-
nosis of acute renal failure described in the medical records—were 
excluded. Patients with cerebral venous thrombosis, or who had 
trauma or surgery within one week of VTE diagnosis, were excluded 
as the associated bleeding risk may have influenced the initial enox-
aparin dose selected.
Data collected include demographics, BMI, radiology reports, 
laboratory data, enoxaparin doses and adjustments, anti- Xa levels, 
and descriptions of any bleeding events. Estimated glomerular filtra-
tion rate (GFR) was calculated utilizing the creatinine–based bedside 
Schwartz equation.24 DVT and PE were diagnosed using duplex ul-
trasonography or venography and computed tomography angiogram, 
respectively.
SD was defined as ≥ 0.90 mg/kg every 12 hours. This cutoff was 
chosen to account for doses rounded down to the nearest 10 mg in-
crement vial. RD was defined as any dose <0.90 mg/kg every 12 hours. 
The duration of anticoagulation treatment varied depending on the 
scenario (ie, spontaneous or provoked).25 Furthermore, the duration 
of enoxaparin used during the treatment time frame varied. As current 
VTE treatment recommends three months of therapy, the final dose 
(and final anti- Xa level) in our study was defined as the last prescribed 
dose (and level) at 90 days of treatment.9
2.2 | Anti- Xa levels and dose adjustments
At our institution, anti- Xa levels drawn after the 2nd through 5th doses 
at 3- 5 hours post- dose are routinely obtained in all patients at the ini-
tiation of enoxaparin. In general, during outpatient follow- up, anti- Xa 
levels are obtained with any dose adjustment or monthly. Following 
ACCP guidelines, therapeutic target anti- Xa level is between 0.5- 1.0 
units/mL. Sub- and supra- therapeutic levels are below and above this 
range, respectively.9
For this study, a dose adjustment was defined as a change of 
enoxaparin dose. The rationale for adjustment was determined by a 
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review of the medical records. The Dade Behring BCS XP instrument 
(Marburg, Germany) was used for measurement of the anti- Xa level, 
with Diagnostica Stago (Parsippany, NJ, USA) or Quest Diagnostics 
(Madison, NJ, USA) anti- Xa chromogenic assays.
2.3 | Outcomes
Retrospective reviews of radiology reports and medical records were 
performed to determine progression and bleeding, respectively. A 
progression was defined as thrombus extension, the development of 
a new PE, or re- thrombosis in a previously treated site, occurring after 
the initiation of enoxaparin. Based on medical record descriptions, 
bleeding events occurring 24 hours after enoxaparin initiation were 
classified as major if they were associated with a decrease in hemo-
globin of ≥2 g/dL within 24 hours of the bleeding event or resulted 
in a blood transfusion. Bleeding events that did not satisfy the crite-
ria for major based on medical record descriptions, were classified as 
minor.
2.4 | Statistical analyses
Summary statistics were calculated. Quantitative data were expressed 
as the mean ± standard deviation and nominal data as a percentage. A 
one sample goodness of fit test was used to compare the progression 
and bleeding rates of our sample relative to the mean rates reported in 
previous studies. Comparisons between the two groups (RD vs SD) for 
quantitative variables were performed using the t- test, with the ex-
ception of the comparison of the number of anti- Xa levels. As this var-
iable was non- normally distributed, the values were log- transformed 
prior to the analysis. For nominal variables, the Fisher’s Exact test was 
All patients (n=30)
Initial treatment dose (mg/kg/dose)
P value<0.90 (RD) (n=19) ≥0.90 (SD) (n=11)
Agea (years) 15.3±1.6 15.3±1.4 15.4±2.1 .940
Male (%) 36.7 31.6 45.5 .696
White (%) 83.3 84.2 81.8 >.999
Weighta (kg) 96.4±22.1 101.8±20.5 87.1±22.6 .078
Heighta (cm) 171.3±10.2 172.4±10.3 169.5±10.2 .464
Obeseb (%) 76.7 84.2 63.6 .372
DVTc 36.7 (11) 36.8 (7) 36.4 (4) >.999
PEc 26.6 (8) 21.1 (4) 36.4 (4) .417
DVT and PEc 36.7 (11) 42.1 (8) 27.2 (3) .466
Thrombolysis at diagnosisc 33.3 (10) 36.8 (7) 27.3 (3) .702
Initial dosea (mg/kg) 0.83±0.14 0.74±0.10 0.98±0.05 <.001
 Range (mg/kg) (0.58- 1.04) (0.58- 0.88) (0.90- 1.04) –
Initial anti- Xa levela (units/mL) 0.70±0.23 0.68±0.20 0.73±0.28 .640
 Sub- therapeutic (<0.5)c – 26.3 (5) 18.2 (2) >.999
 Therapeutic (0.5- 1.0)c – 68.4 (13) 72.7 (8) >.999
 Supra- therapeutic (>1.0)c – 5.3 (1) 9.1 (1) >.999
Median number of anti- Xa levelsd – 3 4 .404
 Range – (1- 8) (1- 14) –
Patients who required dose adjustmentsc – 47.4 (9) 81.8 (9) .063
Final dosea (mg/kg) 0.77±0.14 0.77±0.12 0.78±0.18 .829
 Range (mg/kg) (0.56- 1.13) (0.56- 1.01) (0.56- 1.13) –
Final dose > initial dosec – 21.0 (4) 9.1 (1) .626
Final dose < initial dosec – 21.0 (4) 72.7 (8) .009
Progressionc – 10.5 (2) 9.1 (1) >.999
Bleeding (all events were minor)c – 10.5 (2) 27.3 (3) .327
DVT, deep vein thrombosis; PE, pulmonary embolism; RD, reduced dose enoxaparin; SD, standard dose enoxaparin.
P values refer to comparisons between RD group and SD group.
aMean±standard deviation
bBody mass index ≥ 95th percentile for age and sex
c% (n)
dnumber of anti- Xa levels obtained during 90 days of treatment.
TABLE  1 Comparison of initial treatment dose groups
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used. Significance was assessed at P<.05. Analyses were performed 
using IBM SPSS Statistics v. 22 (Armonk, NY, USA).
3  | RESULTS AND DISCUSSION
The initial database query resulted in 276 patients. Electronic and 
written medical record review resulted in 42 patients, 12 of which 
were excluded for cerebral venous thrombosis (4), recent trauma or 
surgery (3), or renal disease (5), leaving 30 patients in our study group. 
Twenty- seven patients were hospitalized for initial VTE management. 
Of these 27 hospitalized patients, three were transferred from outside 
institutions on enoxaparin plus warfarin (2) or heparin infusion (1) at 
the time of transfer. After 4 weeks of hospitalization, one patient fol-
lowed up with an outside institution for continued VTE management. 
Serum creatinine was available in 21 patients (range 0.53- 0.99 mg/
dL); the estimated GFR was 97.12 mg/min/1.73 m2 (range 69.12- 
143.50 mg/min/1.73 m2). Available unconjugated bilirubin levels 
(n=20), were below 6 mg/dL, the threshold shown to interfere with 
anti- Xa level assays.26 Twenty- nine patients were reportedly negative 
for antithrombin III deficiency.
Nineteen patients initially received RD enoxaparin (Table 1). Mean 
initial anti- Xa level was within therapeutic range and 14/19 (74%) had 
initial therapeutic or supra- therapeutic anti- Xa levels. Five patients 
had initial sub- therapeutic anti- Xa levels, one of whom tested positive 
for a lupus anticoagulant and had a thrombus progression. Of the 19 
patients, 10 (53%) did not require any dose adjustments during treat-
ment; 23 of 27 (85%) anti- Xa levels obtained during their treatment 
were within therapeutic range. The mean initial and final doses were 
not significantly different (Figure 1). Four RD patients’ final doses were 
greater than their initial doses (Table 2). Of these four, two patients 
who were initially dosed at <0.7 mg/kg had thrombus progression de-
spite one patient having an initial supra- therapeutic anti- Xa level. Two 
bleeding events occurred, both of which were minor (Table 1).
F IGURE  1 Mean±standard deviation initial (blue) and final dosing 
(red) for the two study groups. Patients dosed initially at <0.90 mg/
kg (RD) did not significantly increase their dose, while patients dosed 
at ≥0.90 mg/kg (SD) significantly decreased their dose to maintain 
anti- Xa levels within therapeutic range (0.5- 1.0 units/mL)
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Eleven patients received SD (Table 1). Unlike the RD patients, the 
SD patients’ mean final dose was significantly lower than their mean 
initial dose (Figure 1). Notably, in eight patients whose final doses 
were less than their initial doses, six (75%) were dose reduced sec-
ondary to supra- therapeutic anti- Xa levels obtained 2- 16 days from 
initiation of therapy.
Between the two groups, no significant differences were observed 
in demographics, obesity status, type of VTE, and use of thromboly-
sis (Table 1). Despite a significantly lower mean initial dose in the RD 
group compared to the SD group, the mean initial anti- Xa levels and 
mean final doses were similar between the groups (Table 1). There 
were no significant differences in the percentages of patients who had 
initial sub- therapeutic, therapeutic, or supra- therapeutic anti- Xa lev-
els, the number of anti- Xa levels obtained during 90 days of treatment, 
nor in progression or bleeding rates between the two groups (Table 1).
In prior LMWH studies, the reported incidence of progression 
ranged from 1- 7%27,28, and the reported incidence of bleeding ranged 
from 0- 36%.27,29 Utilizing a mean incidence of approximately 5% for 
progression, and 20% for minor bleeding, our RD and SD groups did 
not differ significantly with these mean rates (progression: RD vs 5% 
P=.25; SD vs 5% P=.43, bleeding: RD vs 20% P=.40, SD vs 20% P=.47).
Ultimately, 83% of all patients were on RD at the end of treatment 
or at 90 days from diagnosis (n=25, mean dosing 0.73 ± 0.11 mg/kg), 
with therapeutic or supra- therapeutic anti- Xa levels.
These findings suggest that initial doses calculated using actual 
body weight may be greater than what is needed, which is consistent 
with some previously published reports.12,13,26 Therapeutic or supra- 
therapeutic anti- Xa levels were achieved in 74% of the RD group. 
However, the degree of dose reduction should be cautiously consid-
ered as the two RD progressions occurred in patients who were ini-
tially dosed at <0.7 mg/kg.
Though the role of anti- Xa monitoring for enoxaparin in adult is 
controversial, monitoring in our SD patients showed supra- therapeutic 
levels up to 16 days from the initial dose. The significance of this is un-
known as our sample size is small, but may be secondary to the effects 
that obesity has on enoxaparin pharmacokinetics that have yet to be 
clearly defined.10–14 Until there are more studies regarding the utility 
of anti- Xa levels, overweight individuals should have periodic monitor-
ing, possibly during the first 2 weeks of therapy.16,17
All bleeding events in our study were minor. Compared to the RD 
group, the SD group had a higher percentage. This is more likely sec-
ondary to the small sample size and less likely secondary to overdosing 
in the SD group; two of the three SD group patients had therapeutic 
anti- Xa levels during the bleeding events.
Limitations inherent to retrospective cohort studies at a single 
institution pertain to this preliminary study. Furthermore, outpatient 
factors such as injection methods or timing of anti- Xa level testing 
are confounding variables. The small sample size precludes any con-
clusions regarding efficacy and safety. Nonetheless, as obesity rates 
increase globally, future trials are warranted to evaluate reduced dose 
enoxaparin in the treatment of overweight and obese adolescents 
with VTE. The information reported here offers a beginning for that 
research.
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